Eli Lilly last month trumpeted topline results showing its rheumatoid arthritis med Olumiant could trigger hair regrowth in the autoimmune disease alopecia areata, where no med
Category: Pharmaceuticals
Eli Lilly retakes innovation crown, while Bristol Myers rates most inventive pharma in annual study
If you gave a pharma a molecule, which one would make the most of it? Eli Lilly, according to IDEA Pharma’s most recent evaluation. It ranks
Biogen readies Alzheimer’s hopeful aducanumab for U.S. launch as stateside sales plummet
The next time Biogen reports its quarterly earnings, the world should know whether its controversial Alzheimer’s drug aducanumab sports an FDA approval or whether the
Novo Nordisk, after obesity trial win for injectable semaglutide, plans test for oral version
Fresh off of presenting eye-popping data for its obesity drug candidate semaglutide, Novo Nordisk is upping the ante with a more user-friendly version of the treatment. The
After cost-cutting spree, Teva chief Schultz nabs big pay bump to nearly $16M
In the aftermath of a multi-year cost-cutting spree, generics juggernaut Teva Pharmaceutical Industries has handed its CEO a sizable pay increase. Kåre Schultz’s pay package swelled
AbbVie’s Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Just a few months ago, AbbVie’s Rinvoq was riding high—and racing toward two new indications to boot. But after in-class rival Xeljanz put up some
Bristol Myers, flush with pair of CAR-T approvals, blueprints first cell therapy factory in Europe
Right on the heels of not one, but two CAR-T approvals in the U.S., Bristol Myers Squibb is bolstering its commercial cell therapy ambitions on the other side
With demand uncertain and its U.S. manufacturing in limbo, AstraZeneca still aims to seek FDA nod for COVID-19 vaccine
Its COVID-19 vaccine has been vilified and its manufacturing network has been questioned, but AstraZeneca is still planning to apply for emergency use authorization of
Shareholders to push for detailed COVID-19 pricing strategies from Pfizer, J&J at annual meetings
‘Tis the season of annual shareholder meetings for the world’s largest drugmakers, marking a year that reaped billions in government-backed funding for those involved in the
FDA blasts troubled COVID-19 vaccine producer Emergent for quality control and cleanliness issues
The FDA’s latest inspection of Emergent BioSolutions’ troubled Baltimore plant has raised fresh concerns about the contract manufacturer’s ability to produce COVID-19 vaccines. Emergent, for